UroToday is excited to bring you written conference highlights, written by uro-oncologists from the 2020 AUA Live Virtual Experience, June 27-28 2020.
|
|
|
|
|
|
The American Urological Association Virtual Meeting |
|
|
|
| International Prostate Forum |
| Why Precision Matters: Implications of Genomic Analysis for mCRPC
|
| James Gulley, MD, Ph.D.
|
| In this International Prostate Forum presentation, Dr. James Gulley discussed implications of the genomic analysis for patients with metastatic castration-resistant prostate cancer and why precision medicine for these patients matters. |
|
|
|
|
|
| PSMA Radioligand Therapy: A New Modality Approaches
|
| Kenneth Pienta, MD
|
| In this International Prostate Forum presentation by Dr. Kenneth Pienta at the 2020 AUA Virtual Annual Meeting, he highlights several questions surrounding PSMA imaging that continue to evolve as well as multiple indications for diagnostic PSMA-based imaging that have been extensively explored.
|
|
|
|
|
|
| Reviewing the Current Indispensable Role of Prostate MRI
|
| Peter Pinto, MD
|
| In this International Prostate Forum presentation, Dr. Peter Pinto presents on the role MRI-targeted biopsy in determining the histologic grade of tumors. When MRI visible lesions exist, combined biopsy leads to more detection of all prostate cancers. A combined biopsy will allow physicians to have a more accurate way to diagnose prostate cancer and increase their confidence that they are providing the best treatment for their patients. |
|
|
|
|
|
| 2020 AUA Live Virtual Experience |
| Crossfire: Controversies in Urology: Prostate Cancer Active Surveillance Can Be Done with mpMRI and Biomarkers; Biopsies are No Longer Necessary
|
Mark Emberton, MD, FRCS, Eric Klein, MD, Samir Tanega, MD,
William Catalona, MD, and Christopher Evans, MD
|
| Mark Emberton, Eric Klein, Samir Tanega, William Catalona, and Christopher Evans together provide their viewpoint on a patient case of a man with a PSA of 5.2, who later underwent a prostate biopsy demonstrating Gleason grade Group 1 cancer only in this Crossfire: Controversies in Urology PRO and CON debate.
|
|
|
|
|
|
| State-of-the-Art Lecture: Has Electronic Medical Records Improved Patient Care?
|
| Peter Basch, MD
|
| In a plenary session at the American Urologic Association Virtual Annual Meeting, Peter Basch presented a state of the art lecture addressing the question of whether electronic medical records has Improved Patient Care.
|
|
|
|
|
|
|
|
|
|
|
| Genetic Testing: What the Urologist Needs to Know
|
| Leonard G. Gomella, MD
|
| Leonard Gomella provided the basic concepts in genetic testing for prostate cancer and highlighted that the human genome project began in 1990 and continued until 2003, discovering 3.2 billion base gene pairs. It is important to understand the difference between inherited germline mutations and somatic mutations that can also be detected in tumors and may guide therapy. |
|
|
|
|
|
| Journal of Urology Lecture: Use of Web and Social Media Sources for Physician Education |
| John Davis, MD |
| The annual Journal of Urology Lecture at the 2020 American Urologic Association (AUA) virtual annual meeting was provided this year by Dr. John Davis, discussing the use of the web and social media sources for educating physicians. |
|
|
|
|
|
| Evaluating The Outcomes of Active Surveillance in Gleason Grade Group 2 Prostate Cancer: Prospective Results From the Canary-PASS Cohort |
| Adrian J. Waisman Malaret, MD |
| At the American Urological Association annual virtual meeting, Dr. Adrian J. Waisman Malaret and colleagues presented results of their study assessing the clinical outcomes of men with grade group 1 and grade group 2 prostate cancer undergoing active surveillance in the Canary Prostate Cancer Active Surveillance Study (PASS) cohort. |
|
|
|
|
|
| Comparison of Different Biopsy Schedules Among Men On Active Surveillance: Analysis of the GAP3 Global Consortium Database |
| Monique Roobol, Ph.D., MSc |
| Monique Roobol and colleagues presented results of their study describing the risk of upgrading and conversion to treatment among men on active surveillance, according to the intensity of repeat biopsy during follow-up. This study used the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) database, consisting of more than 20,000 men from 27 centers across the world. |
|
|
|
|
|
 |
|
|
| To view our full coverage of the 2020 AUA Live Virtual Experience, visit the Conference Coverage section on UroToday.com |
|
|
|
|
|
|
 |
|
|
|
 |
